Pivotal role of animal models in the development of new therapies for cytomegalovirus infections

被引:49
作者
Kern, Earl R. [1 ]
机构
[1] Univ Alabama Birmingham, Dept Pediat, Birmingham, AL 35233 USA
关键词
cytomegalovirus; animal models; mouse; rat; guinea pig;
D O I
10.1016/j.antiviral.2006.05.018
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Since human cytomegalovirus (CMV) is extremely species specific and does not replicate in experimental animal tissues, animal models for the evaluation of antiviral agents for these infections have utilized surrogate animal viruses including murine CMV, rat CMV and guinea pig CMV. Murine CMV and rat CMV infections in normal and immunocompromised animals provide models of disseminated infection and are ideal for screening of new agents. While guinea pig CMV infection in immunocompromised animals also provides a model for disseminated disease, the model for congenital CMV is unique among all the experimental models. While these models have played a major role in the development of ganciclovir, foscarnet and cidofovir, they do not provide information directly related to human CMV, nor are they useful for evaluation of agents that are active only against human CMV. The SCID-hu mouse models in which human tissue is infected with human CMV has been very useful in the development of new antiviral agents such as maribavir and cyclopropavir. Collectively these experimental CMV infections provide a variety of models representing various aspects of CMV infection in humans that are highly predictive for antiviral efficacy in humans. (c) 2006 Elsevier B.V. All rights reserved.
引用
收藏
页码:164 / 171
页数:8
相关论文
共 95 条
  • [1] ALFORD CA, 1984, ANTIVIR AGENTS VIR, P443
  • [2] NOVEL METHOD FOR EVALUATING ANTIVIRAL DRUGS AGAINST HUMAN CYTOMEGALOVIRUS IN MICE
    ALLEN, LB
    LI, SX
    ARNETT, G
    TOYER, B
    SHANNON, WM
    HOLLINGSHEAD, MG
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1992, 36 (01) : 206 - 208
  • [3] A RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF ORAL ACYCLOVIR FOR THE PREVENTION OF CYTOMEGALO-VIRUS DISEASE IN RECIPIENTS OF RENAL-ALLOGRAFTS
    BALFOUR, HH
    CHACE, BA
    STAPLETON, JT
    SIMMONS, RL
    FRYD, DS
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1989, 320 (21) : 1381 - 1387
  • [4] Nonhuman primate models of intrauterine cytomegalovirus infection
    Barry, PA
    Lockridge, KM
    Salamat, S
    Tinling, SP
    Yue, YJ
    Zhou, SS
    Gospe, SM
    Britt, WJ
    Tarantal, AF
    [J]. ILAR JOURNAL, 2006, 47 (01) : 49 - 64
  • [5] Bernstein D.I., 1999, HDB ANIMAL MODELS IN, P935
  • [6] BIA FJ, 1983, REV INFECT DIS, V5, P177
  • [7] Oral activity of ether lipid ester prodrugs of cidofovir against experimental human cytomegalovirus infection
    Bidanset, DJ
    Beadle, JR
    Wan, WB
    Hostetler, KY
    Kern, ER
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2004, 190 (03) : 499 - 503
  • [8] Replication of human cytomegalovirus in severe combined immunodeficient mice implanted with human retinal tissue
    Bidanset, DJ
    Rybak, RJ
    Hartline, CB
    Kern, ER
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2001, 184 (02) : 192 - 195
  • [9] BIDANSET DJ, 1999, HDB ANIMAL MODELS IN, P957
  • [10] Rate of emergence of cytomegalovirus (CMV) mutations in leukocytes of patients with acquired immunodeficiency syndrome who are receiving valganciclovir as induction and maintenance therapy for CMV retinitis
    Boivin, G
    Gilbert, C
    Gaudreau, A
    Greenfield, I
    Sudlow, R
    Roberts, NA
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2001, 184 (12) : 1598 - 1602